A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)

← catalyst calendar

NCT06280703 · readout ≤ 42 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · Double · Basic science

Enrollment

118estimated

Sites

Country

Germany

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-05-15

actual

When the study began enrolling

Primary completion

Sep 2026

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Sep 2026

estimated

The whole study's end, after follow-up

First posted

2024-02-28

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-01-20

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Healthy
Type 1 Diabetes Mellitus

Interventions

Drug: LY3938577
Drug: Placebo
Drug: Insulin Degludec
Drug: Insulin Lispro
Drug: LY3938577
Drug: Placebo
Drug: Insulin Degludec
Drug: Basal Insulin
Drug: Lispro Prandial Insulin

Primary outcomes

what the primary-completion date above is the date OF

Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.

measured Baseline up to Approximately Week 11

Part B and D: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.

measured Baseline up to Week 10

Part A: Number of Participants With Clinically Significant Changes in Vital Signs

measured Baseline up to Approximately Week 11

Part B: Number of Participants With Clinically Significant Changes in Vital Signs

measured Baseline up to Week 10

Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters

measured Baseline up to Approximately Week 11

Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters

measured Baseline up to Week 10

Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577